Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Item3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing As previously disclosed, Athersys, Inc. received a written notice...
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to appr...
Athersys, Inc. (NASDAQ:ATHX – Get Free Report) was the target of a significant increase in short interest in September. As of September 30th, there was short interest totalling 993,200 shares, an increase of 25.2% from the September 15th total of 793,500 shares. Based on an average trading volume of 759,600 shares, the days-to-cover ratio is […]
Athersys, Inc. , a cell therapy and regenerative medicine company developing MultiStem® for critical care indications, announces it has entered into a warrant exercise inducement offer letter to...
StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Athersys Stock Performance Shares of NASDAQ ATHX opened at $0.10 on Wednesday. Athersys has a 1 year low of $0.10 and a 1 year […]